

# Nicergoline

Catalog No: tcsc2941



## Available Sizes

**Size:** 10mg

**Size:** 50mg



## Specifications

**CAS No:**

27848-84-6

**Formula:**

$C_{24}H_{26}BrN_3O_3$

**Pathway:**

GPCR/G Protein

**Target:**

Adrenergic Receptor

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 86.67$  mg/mL (178.93 mM)

**Observed Molecular Weight:**

484.39


## Product Description

Nicergoline is an ergot derivative used to treat senile dementia and other disorders with vascular origins.

Target: Alpha-1A adrenergic receptor

Nicergoline acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.

Nicergoline displaced [3H]-prazosin bound to rat forebrain membranes pretreated with chloroethylclonidine ( $pK_i = 9.9 \pm 0.2$ ) at concentrations 60-fold lower than in rat liver membranes ( $pK_i = 8.1 \pm 0.2$ ). Finally, of the nicergoline metabolites studied, lumilysergol acted as a modest  $\alpha_1$  antagonist (bromonicotinic acid was devoid of  $\alpha_1$  antagonist activity). In conclusion, nicergoline is a potent and selective  $\alpha_{1A}$ -adrenoceptor subtype antagonist, an  $\alpha_1$ -adrenoceptor subtype which is mainly represented in resistance arteries [1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!